Jump to main content
Jump to site search

Issue 11, 2018
Previous Article Next Article

Targeting Brd4 for cancer therapy: inhibitors and degraders

Author affiliations


Bromodomain-containing protein 4 (Brd4) plays an important role in mediating the expression of genes involved in cancers and non-cancer diseases such as inflammatory diseases and acute heart failure. Inactivating Brd4 or downregulating its expression inhibits cancer development, leading to the current interest in Brd4 as a promising anticancer drug target. Numerous Brd4 inhibitors have been studied in recent years and some of them are currently in various phases of clinical trials. Recently, selective degradation of target proteins by small bifunctional molecules (PROTACs) has emerged as an attractive drug discovery approach owing to the advantages it could offer over traditional small-molecule inhibitors. A number of Brd4 degraders have been reported and showed more efficient anticancer activities than just protein inhibition. In this review, we will discuss recent findings in the discovery and development of small-molecule inhibitors and degraders that target Brd4 as a potential anticancer agent.

Graphical abstract: Targeting Brd4 for cancer therapy: inhibitors and degraders

Back to tab navigation

Publication details

The article was received on 13 Apr 2018, accepted on 03 Aug 2018 and first published on 07 Aug 2018

Article type: Review Article
DOI: 10.1039/C8MD00198G
Med. Chem. Commun., 2018,9, 1779-1802

  •   Request permissions

    Targeting Brd4 for cancer therapy: inhibitors and degraders

    Y. Duan, Y. Guan, W. Qin, X. Zhai, B. Yu and H. Liu, Med. Chem. Commun., 2018, 9, 1779
    DOI: 10.1039/C8MD00198G

Search articles by author